GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2007

UCB Wins License from Lonza to GS Gene Expression System

  • Lonza granted UCB a nonexclusive, worldwide license to their GS Gene Expression System™ (GS: glutamine synthetase).

    The research evaluation agreement covers the use of the technology for R&D. An option to obtain a license to use the system for commercial purposes is included in the agreement.

    “We believe that having UCB select the GS Gene Expression System underscores the importance of this technology for the efficient production of therapeutic antibodies and recombinant proteins,” says Karen Fallen, commercial licensing manager at Lonza.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »